

H Michael Belmont

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1483609/publications.pdf>

Version: 2024-02-01

35
papers

1,632
citations

430874

18
h-index

434195

31
g-index

38
all docs

38
docs citations

38
times ranked

2065
citing authors

#	ARTICLE	IF	CITATIONS
1	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	1.9	6
2	Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 829-839.	5.6	38
3	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	2.0	19
4	Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021, 8, e000475.	2.7	10
5	Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	61
6	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021, 61, 64.	1.7	0
7	1206...Evaluation of SARS-CoV-2 IgG antibody reactivity in a multi-racial/ethnic cohort of patients with systemic lupus erythematosus. , 2021, , .		2
8	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). <i>Lupus</i> , 2021, 30, 2276-2285.	1.6	21
9	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. <i>Arthritis Care and Research</i> , 2020, 72, 233-242.	3.4	17
10	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	1.6	28
11	Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 1971-1980.	5.6	51
12	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. <i>Arthritis Research and Therapy</i> , 2020, 22, 191.	3.5	21
13	Integrated urine proteomics and renal single-cell genomics identify an IFN- β response gradient in lupus nephritis. <i>JCI Insight</i> , 2020, 5, .	5.0	57
14	3T chemical shift-encoded MRI: Detection of altered proximal femur marrow adipose tissue composition in glucocorticoid users and validation with magnetic resonance spectroscopy. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 490-496.	3.4	16
15	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. <i>Arthritis Care and Research</i> , 2019, 71, 949-960.	3.4	38
16	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080.	3.8	9
17	3T chemical shift-encoded MRI: Detection of altered proximal femur marrow adipose tissue composition in glucocorticoid users and validation with magnetic resonance spectroscopy. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, spcone-spcone.	3.4	10
18	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. <i>Lupus Science and Medicine</i> , 2019, 6, e000344.	2.7	22

#	ARTICLE	IF	CITATIONS
19	Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. <i>Nature Immunology</i> , 2019, 20, 915-927.	14.5	275
20	Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 256-262.	3.4	21
21	CS-31...Safety of hydroxychloroquine withdrawal in older adults with systemic lupus erythematosus. , 2018, , .		1
22	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis and Rheumatology</i> , 2017, 69, 2006-2017.	5.6	126
23	Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. <i>JCI Insight</i> , 2017, 2, .	5.0	164
24	3 Tesla MRI detects deterioration in proximal femur microarchitecture and strength in long-term glucocorticoid users compared with controls. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1489-1496.	3.4	21
25	Rapid aneurysm growth and rupture in systemic lupus erythematosus. , 2015, 6, 9.		15
26	Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. <i>Rheumatology International</i> , 2010, 30, 591-598.	3.0	22
27	Treatment of ANCA-associated systemic vasculitis. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2006, 64, 60-6.	0.7	4
28	Circulating activated endothelial cells in systemic lupus erythematosus: Further evidence for diffuse vasculopathy. <i>Arthritis and Rheumatism</i> , 2001, 44, 1203-1208.	6.7	111
29	Initial management of proliferative lupus nephritis: To cytotoxic or not to cytotoxic?. <i>Current Rheumatology Reports</i> , 1999, 1, 87-88.	4.7	0
30	Lupus Nephritis. <i>BioDrugs</i> , 1999, 11, 7-19.	4.6	1
31	Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1997, 40, 1810-1816.	6.7	155
32	MISOPROSTOL AND PREDNISONE TREATMENT OF LUPUS NEPHRITIS. <i>American Journal of Therapeutics</i> , 1995, 2, 928-932.	0.9	8
33	Up-Regulation of Endothelial Cell Adhesion Molecules Characterizes Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 1994, 37, 376-383.	6.7	171
34	An extended course of pulse cyclophosphamide preserved renal function and reduced the rate of exacerbations in patients with severe lupus nephritis. <i>ACP Journal Club</i> , 1993, 118, 86.	0.1	0
35	Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. <i>Arthritis and Rheumatism</i> , 1992, 35, 1028-1037.	6.7	104